You are here: Industry Insights > Janssen

News List

Janssen laying off 4 dozen employees as California plant heads toward closure fiercepharma
April 03, 2019
Janssen is now focused in other areas and has decided the plant is no longer needed.
Bayer reaches settlement to resolve Xarelto™ litigation worldpharmanews
March 26, 2019
More than five years after the Xarelto™ litigation began, and with Bayer and Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of 775 million U.S. dollars.
Janssen seeks USFDA nod for Darzalex to treat ASCT multiple myeloma biospectrumasia
March 15, 2019
Janssen announced the submission of a supplemental Biologics License Application (sBLA) to FDA for Darzalex to treat ASCT multiple myeloma
Morphic and Janssen collaboratively develop integrin therapies pharmaceutical-technology
February 26, 2019
Biotechnology company Morphic Therapeutic has formed a research and collaboration alliance with Johnson & Johnson subsidiary Janssen for the discovery and development of new integrin therapeutics....
FDA panel supports Janssen’s esketamine nasal spray for depression pharmaceutical-technology
February 14, 2019
Janssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its esketamine nasal spray Spravato to treat adults with treatment-resistant depression.
Janssen announces European Commission approval of ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease firstwordpharma
January 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has granted marketing authorisation for ERLEADA® (apalutamide), a next generation oral androgen receptor inhibitor for the treatment of adult patie
Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis firstwordpharma
January 09, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA®(ustekinumab) for the treatment of adults with moderately
Janssen files Stelara in Europe for ulcerative colitis pharmatimes
January 08, 2019
Janssen has submitted a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC).
Janssen signs a $818m CRISPR products deal with Locus Biosciences pharmaceutical-technology
January 08, 2019
Janssen Pharmaceuticals has signed an exclusive collaboration and licence agreement with biotechnology firm Locus Biosciences for CRISPR products intended to treat bacterial infections.
Janssen signs a $818m CRISPR products deal with Locus Biosciences pharmaceutical-technology
January 07, 2019
Janssen Pharmaceuticals has signed an exclusive collaboration and licence agreement with biotechnology firm Locus Biosciences for CRISPR products intended to treat bacterial infections.....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page